.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Analyze global market entry opportunities
  • Uncover prior art in expired and abandoned patents

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Farmers Insurance
Teva
Julphar
McKesson
Cerilliant
Harvard Business School
US Department of Justice
Fish and Richardson
Baxter
Boehringer Ingelheim

Generated: June 24, 2017

DrugPatentWatch Database Preview

GLUCOVANCE Drug Profile

« Back to Dashboard

What is the patent landscape for Glucovance, and when can generic versions of Glucovance launch?

Glucovance is a drug marketed by Bristol Myers Squibb and is included in one NDA. There is one patent protecting this drug.

This drug has thirty-eight patent family members in twenty-six countries.

The generic ingredient in GLUCOVANCE is glyburide; metformin hydrochloride. There are twenty drug master file entries for this compound. Twenty-four suppliers are listed for this compound. Additional details are available on the glyburide; metformin hydrochloride profile page.

Summary for Tradename: GLUCOVANCE

Patents:1
Applicants:1
NDAs:1
Suppliers / Packagers: see list2
Bulk Api Vendors: see list88
Clinical Trials: see list7
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:GLUCOVANCE at DailyMed

Pharmacology for Tradename: GLUCOVANCE

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Bristol Myers Squibb
GLUCOVANCE
glyburide; metformin hydrochloride
TABLET;ORAL021178-001Jul 31, 2000DISCNYesNo6,303,146*PED► SubscribeY► Subscribe
Bristol Myers Squibb
GLUCOVANCE
glyburide; metformin hydrochloride
TABLET;ORAL021178-002Jul 31, 2000ABRXYesYes6,303,146*PED► SubscribeY► Subscribe
Bristol Myers Squibb
GLUCOVANCE
glyburide; metformin hydrochloride
TABLET;ORAL021178-003Jul 31, 2000ABRXYesNo6,303,146*PED► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: GLUCOVANCE

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
RE38629 Solid oral dosage form comprising a combination of metformin and glibenclamide► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: GLUCOVANCE

Country Document Number Estimated Expiration
European Patent Office2269613► Subscribe
European Patent Office1435240► Subscribe
Russian Federation2003126257► Subscribe
Denmark0974356► Subscribe
European Patent Office0974356► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Mallinckrodt
Cipla
Fish and Richardson
Citi
Harvard Business School
Express Scripts
Dow
Queensland Health
Medtronic
Daiichi Sankyo

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot